Hepatitis C Challenge: Hep C Caring Ambassadors Program
 HepC Choices

Hepatitis News:

April 2006

  New test touted for Hepatitis C victims
"Rockville, Md.-based Celera Genomics said Wednesday it has developed a genetic test to help determine which Hepatitis C sufferers are at greatest risk."

HIV/HCV coinfected patients have a poorer outcome after starting antiretrovirals than those who only have HIV
"HIV-positive individuals who are coinfected with hepatitis C virus have poorer outcomes after starting potent antiretroviral therapy than patients who are only infected with HIV, according to a nationwide Danish study to be published in the May 15th edition of Clinical Infectious Diseases (now online)."

Results Support Dosing Every Two Weeks with Potential for Improved Side Effect Profile Over Current Therapies
"Biolex Therapeutics today announced successful results from the Phase 1 clinical trial of Locteron, a product the company is co-developing with OctoPlus (Leiden, the Netherlands)."

Novelos Therapeutics IND for Novel Hepatitis C Drug is Accepted by FDA; Company Is on Track to Begin Patient Enrollment by July 2006
"Novelos Therapeutics, Inc., a biotechnology company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the Food and Drug Administration (FDA) accepted Novelos' Investigational New Drug Application (IND) for NOV-205, its second clinical stage compound. The initial U.S.-based Phase 1b trial will evaluate NOV-205 as monotherapy for chronic hepatitis C genotype 1 patients who have failed pegylated interferon plus ribavirin therapy."

Transition Therapeutics reports positive data from hepatitis C trial
"Testing of a hepatitis C drug under development by Transition Therapeutics Inc. has returned positive results, the drug company said Friday."

AVI BioPharma Updates On Hepatitis C Virus Clinical Trial Status - Quick Facts
"On Thursday, AVI BioPharma. updated on the status of its multicenter study in patients with chronic active hepatitis C virus infection. The company said that the trial is designed to assess the safety, tolerability, pharmacokinetics and viral response to treatment with AVI's proprietary NEUGENE antisense compound AVI-4065 among healthy volunteers and patients with HCV."

Collaborative Financing From Symphony Capital Partners, LP Designed to Advance Next-Generation TLR-Agonist Pipeline
"Dynavax Technologies announced an agreement with Symphony Capital Partners, LP and its co-investors to provide $50 million of committed capital to advance Dynavax's ISS-based cancer, hepatitis B and hepatitis C therapeutic programs through clinical development."

New Jersey Considers Bills to Curb HIV and Hepatitis C Drug Policy Alliance: New Jersey Considers Bills to Curb HIV and Hepatitis C
"In a state with some of the highest rates of HIV and hepatitis C spread by contaminated syringes, Drug Policy Alliance's New Jersey office is working hard for passage of syringe access legislation."

Trial to test Cangene's WinRho(R) SDF in hepatitis C patients
"Cangene today reports the beginning of a clinical trial at Weill Medical College of Cornell University in New York City that will test Cangene's WinRho(R) SDF in patients infected with hepatitis C virus (HCV)."

Occupational hazard; health care workers have more Hepatitis C
"Health care workers may get infected by the Hepatitis C virus if precautions are not taken in disposing needles and other contaminated materials, according to a new study which found that prevalence of virus was almost double in health care workers in comparison to general population."

Musicians Raise Awareness of Hepatitis C in Missouri - Springfield and Columbia Musicians Join Kelly's Lot to help The Missouri Hepatitis C Alliance Raise Awareness of Hep C
"The Missouri Hepatitis C Alliance (MOHCA) is proud to announce an "Awareness and Screening" program with three concerts by blues and roadhouse rock band Kelly's Lot, national spokesband for the national Hep C Coalition."

Health Risks Shadow EMTs
"The face and hand protections are as much a part of a county ambulance's equipment as oxygen and a backboard. Breathing masks guard against coughed-up blood and saliva; eye goggles and face masks do the same. Disposable rubber gloves are almost a part of the uniform. Older paramedics remember a time when those safeguards weren't there, when they dove in at traumatic scenes bare-handed and inhaled particles from infected lungs without worrying about the tiny pathogens in the blood of the people they treated."

Activists: Hepatitis C clinical trial unfairly excludes blacks
"Two advocacy groups are blasting the decision by pharmaceutical company Schering-Plough to exclude African-Americans from a clinical trial of its experimental hepatitis C treatment, a decision the company says was needed to better gauge the efficacy of the medications, The [Newark] Star-Ledger reports."

County Council to examine controversial needle exchange program
"Yesterday, more than 100 people walked through the parking lot of the Allegheny County Health Department, entered one of the building's narrow hallways, and got fresh supplies of the alcohol swabs, syringes and needles they need to inject illegal drugs into their bloodstream. Proponents would say that Prevention Point Pittsburgh's needle exchange program is an example of a public health measure that has been successfully used around the country to limit the spread of dangerous infections like HIV and hepatitis C."

Safety of nation's blood supply a prime concern for hemophiliacs
"The first people hurt when the nation's blood supply gets tainted are likely to be those whose lives depend on transfusions. That's why blood safety is a major concern of the more than 400 people with hemophilia and other clotting disorders who are attending a national conference in St. Louis starting today."

Clinical Trials, Cohort Studies, Pilot Studies

Hepatitis C virus infection in a resident elderly population: A 10-year follow-up study.
Monica F, et al. Dig Liver Dis. 2006 Apr 14; [Epub ahead of print]

Majority of patients with hepatitis C express physical, mental, and social difficulties with antiviral treatment. Zickmund SL, et al. Eur J Gastroenterol Hepatol. 2006 Apr;18(4):381-8.

Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients. Taliani G, et al. Gastroenterology. 2006 Apr;130(4):1098-106.

Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Berg T, et al. Gastroenterology. 2006 Apr;130(4):1086-97.

Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy. Bocher WO, et al. Liver Int. 2006 Apr;26(3):319-25.

Efficacy and tolerance of interferon-alpha in the treatment of chronic hepatitis C in end-stage renal disease patients on hemodialysis. Rocha CM, et al. Liver Int. 2006 Apr;26(3):305-10.

Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Jensen DM, et al. Hepatology. 2006 Apr 20;43(5):954-960 [Epub ahead of print]

Duration of peginterferon therapy in acute hepatitis C: A randomized trial. Kamal SM, et al. Hepatology. 2006 Apr 20;43(5):923-931 [Epub ahead of print]

Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection.
Perumalswami P, et al. Hepatology. 2006 Apr;43(4):780-7.

Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis. Kamal SM, et al. Hepatology. 2006 Apr;43(4):771-9.

Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C.
Sanyal AJ, et al. Hepatology. 2006 Apr;43(4):682-9.

Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin*. Brau N, et al. J Viral Hepat. 2006 Apr;13(4):242-9.

Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Walsh MJ, et al.
Gut. 2006 Apr;55(4):529-35. Epub 2005 Nov 18.

Chronic Hepatitis C in Patients With Persistently Normal Alanine Transaminase Levels. Shiffman ML, et al. Clin Gastroenterol Hepatol. 2006 Apr 19; [Epub ahead of print]

Assessment of liver fibrosis progression in patients with chronic hepatitis C and normal alanine aminotransferase values: The role of AST to the platelet ratio index. Fabris C, et al. Clin Biochem. 2006 Apr;39(4):339-43. Epub 2006 Feb 20.

Basic And Applied Science, Pre-Clinical Studies

Oval cells in hepatitis B virus-positive and hepatitis C virus-positive liver cirrhosis: histological and ultrastructural study. Sun C, Jin XL, Xiao JC. Histopathology. 2006 Apr;48(5):546-55.

Productive replication of hepatitis C virus in perihepatic lymph nodes in vivo: implications of HCV lymphotropism. Pal S, et al. Gastroenterology. 2006 Apr;130(4):1107-16.

The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Paeshuyse J, et al. Hepatology. 2006 Apr;43(4):761-70.

Antiproliferative effects of interferon alpha on hepatic progenitor cells in vitro and in vivo.
Lim R, et al. Hepatology. 2006 Apr 20;43(5):1074-1083 [Epub ahead of print]

Genomic response to interferon-alpha in chimpanzees: Implications of rapid downregulation for hepatitis C kinetics. Lanford RE, Guerra B, Lee H, Chavez D, Brasky KM, Bigger CB. Hepatology. 2006 Apr 20;43(5):961-972 [Epub ahead of print]

The interaction of natural hepatitis C virus with human scavenger receptor SR-BI/Cla1 is mediated by ApoB-containing lipoproteins. Maillard P, FASEB J. 2006 Apr;20(6):735-7. Epub 2006 Feb 13.

Interferon-alpha/beta upregulate IL-15 expression in vitro and in vivo: analysis in human hepatocellular carcinoma cell lines and in chronic hepatitis C patients during interferon-alpha/beta treatment.
Yamaji K, et al. Cancer Immunol Immunother. 2006 Apr;55(4):394-403. Epub 2005 Jul 22.

Human hepatocytes secrete soluble CD14, a process not directly influenced by HBV and HCV infection.
Meuleman P, et al. Clin Chim Acta. 2006 Apr;366(1-2):156-62. Epub 2005 Oct 25.

Hepatitis C virus (HCV) core protein enhances the immunogenicity of a co-delivered DNA vaccine encoding HCV structural antigens in mice. Alvarez-Lajonchere L, et al. Biotechnol Appl Biochem. 2006 Apr;44(Pt 1):9-17.

Expression and processing of hepatitis C virus structural proteins in Pichia pastoris yeast.
Martinez-Donato G, et al. Biochem Biophys Res Commun. 2006 Apr 7;342(2):625-31. Epub 2006 Feb 8.

Role of p38 MAPK and RNA-dependent Protein Kinase (PKR) in Hepatitis C Virus Core-dependent Nuclear Delocalization of Cyclin B1. Spaziani A, Alisi A, Sanna D, Balsano C. J Biol Chem. 2006 Apr 21;281(16):10983-9. Epub 2006 Jan 30.

HIV/HCV Coinfection

Immunosuppression, Hepatitis C Infection, and Acute Renal Failure in HIV-infected Patients.
Franceschini N, Napravnik S, Finn WF, Szczech LA, Eron JJ Jr. J Acquir Immune Defic Syndr. 2006 Apr 24; [Epub ahead of print]

Progression to Cirrhosis in Latinos With Chronic Hepatitis C: Differences in Puerto Ricans With and Without Human Immunodeficiency Virus Coinfection and Along Gender. Rodriguez-Torres M, et al. J Clin Gastroenterol. 2006 Apr;40(4):358-366.

Importance of hepatitis C coinfection in the development of QT prolongation in HIV-infected patients.
Nordin C, et al. J Electrocardiol. 2006 Apr;39(2):199-205. Epub 2005 Nov 28.

Gene Expression Profiles in Hepatitis C Virus (HCV) and HIV Coinfection: Class Prediction Analyses before Treatment Predict the Outcome of Anti-HCV Therapy among HIV-Coinfected Persons.
Lempicki RA, et al. J Infect Dis. 2006 Apr 15;193(8):1172-7. Epub 2006 Mar 13.

Impact of Hepatitis C Virus Coinfection on Response to Highly Active Antiretroviral Therapy and Outcome in HIV-Infected Individuals: A Nationwide Cohort Study. Weis N, et al. Clin Infect Dis. 2006 May 15;42(10):1481-7. Epub 2006 Apr 12.

Predictors of liver fibrosis in HIV-infected patients with chronic hepatitis C virus (HCV) infection: assessment using transient elastometry and the role of HCV genotype 3. Barreiro P, et al. Clin Infect Dis. 2006 Apr 1;42(7):1032-9. Epub 2006 Feb 21.

HCV and HIV infection and co-infection: injecting drug use and sexual behavior, AjUDE-Brasil I Project.
Zocratto KB, et al. Cad Saude Publica. 2006 Apr;22(4):839-848. Epub 2006 Apr 5.

Efficacy and Safety of Pegylated Interferon-alpha2b Plus Ribavirin for the Treatment of Chronic Hepatitis C in HIV-Infected Patients. Santin M, et al. AIDS Res Hum Retroviruses. 2006 Apr;22(4):315-20.

Cryoglobulinaemia vasculitis in patients coinfected with HIV and hepatitis C virus. Saadoun D, Aaron L, Resche-Rigon M, Pialoux G, Piette JC, Cacoub P; GERMIVIC Study Group. AIDS. 2006 Apr 4;20(6):871-7.

Racial difference in mortality among U.S. veterans with HCV/HIV coinfection.
Merriman NA, Porter SB, Brensinger CM, Reddy KR, Chang KM. Am J Gastroenterol. 2006 Apr;101(4):760-7. Epub 2006 Feb 22.

Complementary And Alternative Therapies

Prediagnostic level of serum retinol in relation to reduced risk of hepatocellular carcinoma. Yuan JM, Gao YT, Ong CN, Ross RK, Yu MC. J Natl Cancer Inst. 2006 Apr 5;98(7):482-90.

Acute hepatitis induced by Chinese hepatoprotective herb, xiao-chai-hu-tang. Hsu LM, Huang YS, Tsay SH, Chang FY, Lee SD. J Chin Med Assoc. 2006 Feb;69(2):86-8.

Polyphenols and gastrointestinal diseases. Dryden GW, Song M, McClain C. Curr Opin Gastroenterol. 2006 Mar;22(2):165-70.

Miscellaneous Works

Assessing patients' understanding of hepatitis C virus infection and its impact on their lifestyle.
Fabris P, et al. Aliment Pharmacol Ther. 2006 Apr 15;23(8):1161-70.

Patient age is a strong independent predictor of 13C-aminopyrine breath test results: a comparative study with histology, duplex-Doppler and a laboratory index in patients with chronic hepatitis C virus infection.
Schneider AR, et al. Clin Exp Pharmacol Physiol. 2006 Apr;33(4):300-4.

Effectiveness of a Screening Program for Hepatitis C. Cheung RC, Cunningham BA, Cooper AD. Dig Dis Sci. 2006 Apr 27; [Epub ahead of print]

Analysis of a hepatitis C screening programme for US veterans. Zuniga IA, et al. Epidemiol Infect. 2006 Apr;134(2):249-57.

Relationship between hepatitis C and chronic kidney disease: results from the Third National Health and Nutrition Examination Survey. Tsui JI, Vittinghoff E, Shlipak MG, O'Hare AM. J Am Soc Nephrol. 2006 Apr;17(4):1168-74. Epub 2006 Mar 8.

Socio-economic characteristics, quality of life, and state of knowledge of patients with hepatitis C viral infection in Germany - socio-economical aspects in hepatitis C.[Article in German] Niederau C, Bemba G, Kautz A. Z Gastroenterol. 2006 Apr;44(4):305-17.

Provider-patient in-office discussions of response to hepatitis C antiviral therapy and impact on patient comprehension. Hamilton HE, Nelson M, Martin P, Cotler SJ. Clin Gastroenterol Hepatol. 2006 Apr;4(4):507-13.

Donate Now Give a gift in celebration
Give a gift in memory
Shop for Us

2 out of 3 people do not know they have hepatitis C.